Compare Inovio Pharmaceuticals Inc (INO) vs SS&C Technologies Holdings Inc. Common Stock (SSNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs SS&C Technologies Holdings Inc. Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.03 (market cap $101.95M), while SS&C Technologies Holdings Inc. Common Stock trades at $83.44 (market cap $19.25B). The key difference: SS&C Technologies Holdings Inc. Common Stock is far larger — about 188.8× Inovio Pharmaceuticals Inc's market cap, and SS&C Technologies Holdings Inc. Common Stock pays a 1.46% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and SS&C Technologies Holdings Inc. Common Stock for 0 Days on average.
| INO | SSNC | |
|---|---|---|
Market Cap | $101.95M | $19.25B |
Volume | 2,985,847 | 1,341,767 |
Sector | Health | Technology |
52-Week High | $2.60 | $89.62 |
52-Week Low | $0.66 | $62.05 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $73.28M | $26.59B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 but has beaten EPS estimates for three consecutive quarters. Key focus remains on the FDA's October 30, 2026 PDUFA decision for INO-3107, its lead candidate for recurrent respiratory papillomatosis. Analyst consensus is bullish with a $2.75 price target, though financials reveal significant losses with a -130,000% net income margin and negative cash flow from operations.
The investment case hinges on regulatory approval of INO-3107, offering substantial upside if successful. However, high cash burn, persistent losses, and dependence on financing pose severe risks. With 59% of analysts rating Buy, the stock presents a high-risk, high-reward opportunity suitable only for speculative investors comfortable with binary outcomes.
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →
